RIA
NBIX icon

Regal Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Regal Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,743
Closed -$213K – 173
2020
Q2 		$213K Buy
+1,743
New +$193K 0.04% 300

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Regal Investment Advisors's NBIX Position: Q3 2020 in Review

Regal Investment Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 1,743 shares — an estimated $213K sold.

Regal Investment Advisors first reported a position in NBIX in Q2 2020 and held it in 1 quarter. The position peaked at $213K in Q2 2020. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • Regal Investment Advisors reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • Regal Investment Advisors sold 1,743 Neurocrine Biosciences shares in Q3 2020, an estimated $213K.
  • Regal Investment Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 1 quarter.
  • Regal Investment Advisors's Neurocrine Biosciences position peaked at $213K in Q2 2020.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Regal Investment Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.